Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2010 Jan 14:697–747. [Article in German] doi: 10.1007/978-3-642-01544-1_51

Hämostyptika

J Koscielny 3, C Jámbor 4, C F Weber 5, P Hellstern 6, C von Heymann 7, A Greinacher 8, H-G Kopp 9, R Möhle 10, L Kanz 9
Editors: Bernd Pötzsch1, Katharina Madlener2
PMCID: PMC7124019

Zusammenfassung

Desmopressin (DDAVP) wurde 1966 als Abkömmling des antidiuretischen Hypophysenhormons Arginin-Vasopressin synthetisch hergestellt. Zu den antidiuretischen Indikationen zählen Diabetes insipidus und Enuresis nocturna, zudem wird es in Tests zur Bestimmung der Nierenkonzentrationsfähigkeit verwendet

Literatur

  1. Balduini C.L., Noris P., Belletti S., Spedini P., Gamba G. In vitro and in vivo effects of desmopressin on platelet function. Haematologica. 1999;84:891–896. [PubMed] [Google Scholar]
  2. Burroughs A.K., Matthews K., Qadiri M., Thomas N., Kernoff P., Tuddenham E., McIntyre N. Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed) 1985;291(6506):1377–81. doi: 10.1136/bmj.291.6506.1377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Budde U., Schaefer G., Mueller N., Egli H., Dent J., Ruggeri Z., Zimmerman T. Acquired von Willebrand’s disease in the myeloproliferative syndrome. Blood. 1984;64(5):981–5. [PubMed] [Google Scholar]
  4. Carless P.A., Henry D.A., Moxey A.J., O’Connell D., McClelland B., Henderson K.M., Sly K., Laupacis A., Fergusson D. Desmopressin for minimizing perioperative allogeneic blood transfusion (Review) Cochrane Library. 2006;3:1–40. [Google Scholar]
  5. De La Fuente B., et al. Response of patients with mild and moderate hemophilia Aand von Willebrand disease to treatment with desmopressin. Ann Int Med. 1985;103:6–14. doi: 10.7326/0003-4819-103-1-6. [DOI] [PubMed] [Google Scholar]
  6. De Marco L., Girolami A., Zimmerman T.S., Ruggeri Z.M. von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest. 1986;77(4):1272–7. doi: 10.1172/JCI112430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Despotis G.J., et al. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet. 1999;354(9173):106–10. doi: 10.1016/S0140-6736(98)12494-7. [DOI] [PubMed] [Google Scholar]
  8. Emmeis J.J., van den Eijnden-Schrauwen Y., van den Hoogen C.M., de Priester W., Westmuckett A., Lupu F. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol. 1997;139:245–56. doi: 10.1083/jcb.139.1.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Franchini M. The use of desmopressin as a hemostatic agent: A concise review. Am J Hematol. 2007;82:822–825. doi: 10.1002/ajh.20940. [DOI] [PubMed] [Google Scholar]
  10. Franchini M., Giuseppe L., Veneri D. Efficacy of desmopressin in preventing hemorrhagic complications in a patient with Marfan syndrome undergoing cardiac surgery. Blood Coagul Fibrinolysis. 2006;17:325–326. doi: 10.1097/01.mbc.0000224855.88366.4c. [DOI] [PubMed] [Google Scholar]
  11. Ibbotson S.H., Grant P.J., Kerry R., Findlay V.S., Prentice C.R. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro. Thromb Haemost. 1991;65(1):64–6. [PubMed] [Google Scholar]
  12. Johnstone M.T., Andrews T., Ware J.A., Rudd M.A., George D., Weinstein M., Loscalzo J. Bleeding time prolongation with streptokinase and its reduction with 1-desamino-8-D-arginine vasopressin. Circulation. 1990;82(6):2142–51. doi: 10.1161/01.cir.82.6.2142. [DOI] [PubMed] [Google Scholar]
  13. Kanwar S., Woodman R.C., Poon M.C., Murohara T., Lefer A.M., Davenpeck K.L., Kubes P. Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules. Blood. 1995;86:2760–2766. [PubMed] [Google Scholar]
  14. Kauffmann J.E., Iezzi M., Vischer U.M. Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor-and cAMP-mediating signalling. J Thromb Haemos. 2003;1:821–828. doi: 10.1046/j.1538-7836.2003.00197.x. [DOI] [PubMed] [Google Scholar]
  15. Kesteven P.J., Holland L.J., Lawrie A.S., Savidge G.F. Inhibitor to factor VIII in mild haemophilia. Thromb Haemost. 1984;52(1):50–2. [PubMed] [Google Scholar]
  16. Kobrinsky N.L., et al. Shortening of bleeding time by 1-desamino-8-D-arginine vasopressin in various bleeding disorders. Lancet. 1984;1:1145–1148. doi: 10.1016/S0140-6736(84)91393-X. [DOI] [PubMed] [Google Scholar]
  17. Koscielny J., Kiesewetter H., Tempelhoff G.F. Platelet Function Analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemostasis. 2006;4:1426–27. doi: 10.1111/j.1538-7836.2006.02001.x. [DOI] [PubMed] [Google Scholar]
  18. Koscielny J., Tempelhoff G.F., Ziemer S., Radtke H., Schmutzler M., Sinha P., Salama A., Kiesewetter H., Latza R. A Practical Concept for Preoperative Management in Patients with Impaired Primary Hemostasis. Clinical and Applied Thrombosis/Hemostasis. 2004;10:155–166. doi: 10.1177/107602960401000206. [DOI] [PubMed] [Google Scholar]
  19. Koscielny J., Blaicher A.M., Felfernig D., Latza R., Wenzel E., Kiesewetter H. Consensus use of desmopressin and antifibrinolytics in three university clinics. Anaesthesia. 1998;53:60–62. doi: 10.1111/j.1365-2044.1998.tb15160.x. [DOI] [PubMed] [Google Scholar]
  20. Koscielny J., Radtke H., Ziemer S., Pindur G., Jung F., Kiesewetter H., Wenzel E. Normalisierung der Thrombozytenfunktion durch Desmopressin. Präoperativer Einsatz bei durch Acetylsalicylsäure (ASS) und nichtsteroidale Analgetika induzierter Thrombozytopathie. Anästh Intensivmed. 1995;36:205–210. [Google Scholar]
  21. Lazarchick J., Conroy J.M. The effect of 6% hydroxyethyl starch and desmopressin infusion on von Willebrand factor: ristocetin cofactor activity. Ann Clin Lab Sci. 1995;25(4):306–9. [PubMed] [Google Scholar]
  22. Lethagen S., Nilsson I.M. DDAVP-induced enhancement of platelet retention: its dependence on platelet-von Willebrand factor and the platelet receptor GP IIb/IIIa. Eur J Haematol. 1992;42:7–13. doi: 10.1111/j.1600-0609.1992.tb00906.x. [DOI] [PubMed] [Google Scholar]
  23. Lethagen S., et al. Effects of desmopressin acetate (DDAVP) and dextran on hemostatic and thromboprophylactic mechanisms. Acta Chir Scand. 1990;156:597–602. [PubMed] [Google Scholar]
  24. Mannucci P.M. Treatment of von Willebrand’ s Disease. N Engl J Med. 2004;351(7):683–94. doi: 10.1056/NEJMra040403. [DOI] [PubMed] [Google Scholar]
  25. Mannucci P.M., Carlsson S., Harris A.S. Desmopressin, surgery and thrombosis. Thromb Haemost. 1994;71:154–155. [PubMed] [Google Scholar]
  26. Mannucci P.M. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood. 1988;72:1449–1455. [PubMed] [Google Scholar]
  27. Mannucci P.M. Desmopressin (DDAVP) for treatment of disorders of hemostasis. Progr Hemost Thromb. 1986;8:19–45. [PubMed] [Google Scholar]
  28. Mannucci P.M., et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Eng J Med. 1983;308:8–12. doi: 10.1056/NEJM198301063080102. [DOI] [PubMed] [Google Scholar]
  29. Mannucci P.M., et al. DDAVP: a new pharmacological approach to the management of hemophilia and von Willebrand disease. Lancet. 1977;1:869–872. doi: 10.1016/S0140-6736(77)91197-7. [DOI] [PubMed] [Google Scholar]
  30. Mannucci P.M., et al. Studies on the prolonged bleeding time in von Willebrand disease. J Lab Clin Med. 1976;88:662–671. [PubMed] [Google Scholar]
  31. Marti G.E., Rick M.E., Sidbury J., Gralnick H.R. DDAVP infusion in five patients with type Ia glycogen storage disease and associated correction of prolonged bleeding times. Blood. 1986;68(1):180–4. [PubMed] [Google Scholar]
  32. Pereira A., del Valle Onorato M., Sanz C. DDAVP enhances the ability of blood monocytes to form rosettes with activated platelets by increasing the expression of P-selectin sialylated ligands on the monocyte surface. Br J Haematol. 2003;120:814–20. doi: 10.1046/j.1365-2141.2003.04180.x. [DOI] [PubMed] [Google Scholar]
  33. Pfueller S.L., Howard M.A., White J.G., Menon C., Berry E.W. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome. Thromb Haemost. 1987;58(4):1060–3. [PubMed] [Google Scholar]
  34. Rodeghiero F. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand disease and hemophilia A. Blood. 1989;74:1997–2000. [PubMed] [Google Scholar]
  35. Sakariassen K.S., Cattaneo M., Berg A., Ruggeri Z.M., Mannucci P.M., Sixma J.J. DDAVP enhancesplatelet adherence and platelet microplates and enhanced procoagulant activity. Thromb Res. 1995;79:163–174. doi: 10.1016/0049-3848(95)00102-W. [DOI] [PubMed] [Google Scholar]
  36. Salzman E.W., Weinstein M.J., Weintraub R.M., et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery: A double-blind randomized trial. N Engl J Med. 1986;314:1402–1406. doi: 10.1056/NEJM198605293142202. [DOI] [PubMed] [Google Scholar]
  37. Schulman S. DDAVP — The multipotent drug in patients with coagulopathies. Transfusion Med Rev. 1991;2:132–144. doi: 10.1016/s0887-7963(91)70200-9. [DOI] [PubMed] [Google Scholar]
  38. Schulman S., Johnsson H. Heparin, DDAVP and the bleeding time. Thromb Haemost. 1991;65:242–244. [PubMed] [Google Scholar]
  39. Sloand E.M., Alyono D., Klein H.G. 1-deamino-8-D-arginine vasopressin (DDAVP) increasesplatelet membrane expression of glycoprotein Ib in patients with disorders of platelet functionand after cardiopulmonary bypass. Am J Hematol. 1994;46:199–207. doi: 10.1002/ajh.2830460308. [DOI] [PubMed] [Google Scholar]
  40. Theiss W., Sauer E. DDAVP: alternative to replacement treatment in mild haemophilia A and von Willebrand-Jurgens syndrome. Dtsch Med Wochenschr. 1977;102(48):1769–72. doi: 10.1055/s-0028-1105576. [DOI] [PubMed] [Google Scholar]
  41. Von Blohn G., Kohler M., Hellstern P., Miyashita C., Wenzel E. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP) Thromb Haemost. 1986;55(1):108–11. [PubMed] [Google Scholar]
  42. Watson A.J., Keogh J.A. Effect of 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure. Nephron. 1982;32(1):49–52. doi: 10.1159/000182801. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Bartholomew J.R., Salgia R., Bell W.R. Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch Intern Med. 1989;149(9):1959–61. doi: 10.1001/archinte.149.9.1959. [DOI] [PubMed] [Google Scholar]
  2. Baubillier E., Cherqui D., Dominique C., Khalil M., Bonnet F., Fagniez P.L., Duvaldestin P. A fatal thrombotic complication during liver transplantation after aprotinin administration. Transplantation. 1994;57(11):1664–6. [PubMed] [Google Scholar]
  3. Beierlein W., Scheule A.M., Dietrich W., Ziemer G. Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. Ann Thorac Surg. 2005;79(2):741–8. doi: 10.1016/j.athoracsur.2004.03.072. [DOI] [PubMed] [Google Scholar]
  4. Bonnar J., Sheppard B.L. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ. 1996;313(7057):579–82. doi: 10.1136/bmj.313.7057.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brown J.R., Birkmeyer N.J., O’Connor G.T. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation. 2007;115(22):2801–13. doi: 10.1161/CIRCULATIONAHA.106.671222. [DOI] [PubMed] [Google Scholar]
  6. Chabbat J., Porte P., Tellier M., Steinbuch M. Aprotinin is a competitive inhibitor of the factor VIIa-tissue factor complex. Thromb Res. 1993;71(3):205–15. doi: 10.1016/0049-3848(93)90095-6. [DOI] [PubMed] [Google Scholar]
  7. Colucci M., Binetti B.M., Branca M.G., Clerici C., Morelli A., Semeraro N., Gresele P. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology. 2003;38(1):230–7. doi: 10.1053/jhep.2003.50277. [DOI] [PubMed] [Google Scholar]
  8. Cramer E.M., Lu H., Caen J.P., Soria C., Berndt M.C., Tenza D. Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation. Blood. 1991;77(4):694–9. [PubMed] [Google Scholar]
  9. Dowd N.P., Karski J.M., Cheng D.C., Carroll J.A., Lin Y., James R.L., Butterworth J. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology. 2002;97(2):390–9. doi: 10.1097/00000542-200208000-00016. [DOI] [PubMed] [Google Scholar]
  10. Fergusson D.A., Hebert P.C., Mazer C.D., et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319–31. doi: 10.1056/NEJMoa0802395. [DOI] [PubMed] [Google Scholar]
  11. Fitzsimons M.G., Peterfreund R.A., Raines D.E. Aprotinin administration and pulmonary thromboembolism during orthotopic liver transplantation: report of two cases. Anesth Analg. 2001;92(6):1418–21. doi: 10.1097/00000539-200106000-00012. [DOI] [PubMed] [Google Scholar]
  12. Forbes C.D., Barr R.D., Reid G., Thomson C., Prentice C.R., McNicol G.P., Douglas A.S. Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. Br Med J. 1972;2(5809):311–3. doi: 10.1136/bmj.2.5809.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Görlinger K. Gerinnungsmanagement bei Lebertransplantationen. Hämostaseologie. 2006;26(3 Suppl 1):S64–76. [PubMed] [Google Scholar]
  14. Görlinger K., Vorweg M., Hanke A., Monaca E., Wappler F., Peters J. Gerinnungsmanagement beim Polytrauma auf der Grundlage eines ROTEM-basierten Algorithmus. Intensivmed. 2006;43(Suppl1):87. [Google Scholar]
  15. Groenland T.H., Porte R.J. Antifibrinolytics in liver transplantation. Int Anesthesiol Clin. 2006;44(3):83–97. doi: 10.1097/01.aia.0000210804.39545.66. [DOI] [PubMed] [Google Scholar]
  16. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol. 2004;11(5):346–50. doi: 10.1097/01.moh.0000137915.88478.23. [DOI] [PubMed] [Google Scholar]
  17. Henry DA, Moxey AJ, Carless PA, O’Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D (2001) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev (1): CD001886 [DOI] [PubMed]
  18. Henry D.A., O’Connell D.L. Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage. BMJ. 1989;298(6681):1142–6. doi: 10.1136/bmj.298.6681.1142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hill G.E., Pohorecki R., Alonso A., Rennard S.I., Robbins R.A. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg. 1996;83(4):696–700. doi: 10.1097/00000539-199610000-00006. [DOI] [PubMed] [Google Scholar]
  20. Jambor C., Görlinger K. Einsatz von Antifibrinolytika bei Massivtransfusionen. A&I. 2007;48:167–173. [Google Scholar]
  21. Karkouti K., Beattie W.S., Dattilo K.M., McCluskey S.A., Ghannam M., Hamdy A., Wijeysundera D.N., Fedorko L., Yau T.M. A propensity score case-control comparison of aprotinin and tranexamic acid in hightransfusion-risk cardiac surgery. Transfusion. 2006;46(3):327–38. doi: 10.1111/j.1537-2995.2006.00724.x. [DOI] [PubMed] [Google Scholar]
  22. Khan M.M., Gikakis N., Miyamoto S., Rao A.K., Cooper S.L., Edmunds L.H., Jr, Colman R.W. Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass. Ann Thorac Surg. 1999;68(2):473–8. doi: 10.1016/S0003-4975(99)00551-2. [DOI] [PubMed] [Google Scholar]
  23. Landis R.C., Haskard D.O., Taylor K.M. New antiinflammatory and platelet-preserving effects of aprotinin. Ann Thorac Surg. 2001;72(5):S1808–13. doi: 10.1016/S0003-4975(01)03193-9. [DOI] [PubMed] [Google Scholar]
  24. Lang T., von Depka M. Possibilities and limitations of thrombelastometry/-graphy. Hamostaseologie. 2006;26(3 Suppl 1):S20–9. [PubMed] [Google Scholar]
  25. Laupacis A., Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg. 1997;85(6):1258–67. doi: 10.1097/00000539-199712000-00014. [DOI] [PubMed] [Google Scholar]
  26. Lucas-Polomeni M.M., Delaval Y., Menestret P., Delaval P., Ecoffey C. A case of anaphylactic shock with tranexamique acid (Exacyl) Ann Fr Anesth Reanim. 2004;23(6):607–9. doi: 10.1016/j.annfar.2004.04.012. [DOI] [PubMed] [Google Scholar]
  27. Mangano D.T., Miao Y., Vuylsteke A., et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. Jama. 2007;297(5):471–9. doi: 10.1001/jama.297.5.471. [DOI] [PubMed] [Google Scholar]
  28. Mangano D.T., Tudor I.C., Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354(4):353–65. doi: 10.1056/NEJMoa051379. [DOI] [PubMed] [Google Scholar]
  29. Mannucci P.M. Hemostatic drugs. N Engl J Med. 1998;339(4):245–53. doi: 10.1056/NEJM199807233390407. [DOI] [PubMed] [Google Scholar]
  30. Mojcik C.F., Levy J.H. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg. 2001;71(2):745–54. doi: 10.1016/S0003-4975(00)02218-9. [DOI] [PubMed] [Google Scholar]
  31. Oudijk E.J., Nieuwenhuis H.K., Bos R., Fijnheer R. Elastase mediated fibrinolysis in acute promyelocytic leukemia. Thromb Haemost. 2000;83(6):906–8. [PubMed] [Google Scholar]
  32. Paparella D., Brister S.J., Buchanan M.R. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med. 2004;30(10):1873–81. doi: 10.1007/s00134-004-2388-0. [DOI] [PubMed] [Google Scholar]
  33. Pfanner G., Kilgert K. Haemorrhagic complications in obstetrics. Hamostaseologie. 2006;26(3 Suppl 1):S56–63. [PubMed] [Google Scholar]
  34. Pietsch U.C., Schaffranietz L. Anaesthesiological management in orthotopic liver transplantation — results of a survey. Anasthesiol Intensivmed Notfallmed Schmerzther. 2006;41(1):21–6. doi: 10.1055/s-2005-861418. [DOI] [PubMed] [Google Scholar]
  35. Quinton T.M., Kim S., Derian C.K., Jin J., Kunapuli S.P. Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. J Biol Chem. 2004;279(18):18434–9. doi: 10.1074/jbc.M401431200. [DOI] [PubMed] [Google Scholar]
  36. Ramsay M.A., Randall H.B., Burton E.C. Intravascular thrombosis and thromboembolism during liver transplantation: antifibrinolytic therapy implicated? Liver Transpl. 2004;10(2):310–4. doi: 10.1002/lt.20064. [DOI] [PubMed] [Google Scholar]
  37. Schoechl H. Coagulation management in major trauma. Hamostaseologie. 2006;26(3 Suppl 1):S52–5. [PubMed] [Google Scholar]
  38. Veres G., Radovits T., Schultz H., Lin L.N., Hutter J., Weigang E., Szabolcs Z., Szabo G. Effect of recombinant aprotinin on postoperative blood loss and coronary vascular function in a canine model of cardiopulmonary bypass. Eur J Cardiothorac Surg. 2007;32(2):340–5. doi: 10.1016/j.ejcts.2007.02.039. [DOI] [PubMed] [Google Scholar]
  39. Wachtfogel Y.T., Kucich U., Hack C.E., Gluszko P., Niewiarowski S., Colman R.W., Edmunds L.H., Jr Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993;106(1):1–9. [PubMed] [Google Scholar]
  40. Walsh P.N., Rizza C.R., Matthews J.M., et al. Epsilon-Aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial. Br J Haematol. 1971;20(5):463–75. doi: 10.1111/j.1365-2141.1971.tb07061.x. [DOI] [PubMed] [Google Scholar]
  41. Xia V.W., Steadman R.H. Antifibrinolytics in orthotopic liver transplantation: current status and controversies. Liver Transpl. 2005;11(1):10–8. doi: 10.1002/lt.20275. [DOI] [PubMed] [Google Scholar]
  42. Zufferey P., Merquiol F., Laporte S., Decousus H., Mismetti P., Auboyer C., Samama C.M., Molliex S. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology. 2006;105(5):1034–46. doi: 10.1097/00000542-200611000-00026. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Alexander J.W., Ogle C.K., Stinnet J.D., et al. Fresh-frozen plasma versus plasma protein derivative as adjunctive therapy for patients with massive burns. J Trauma. 1979;19:502–511. [PubMed] [Google Scholar]
  2. Alvarez-Larrán A., Del Rio J., Ramírez C., et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang. 2004;86:246–251. doi: 10.1111/j.0042-9007.2004.00506.x. [DOI] [PubMed] [Google Scholar]
  3. Aquilar M.I., Hart R.G., Kase C.S., et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc. 2007;82:82–92. doi: 10.4065/82.1.82. [DOI] [PubMed] [Google Scholar]
  4. Atance R., Pereira A., Ramírez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion. 2001;41:1548–1552. doi: 10.1046/j.1537-2995.2001.41121548.x. [DOI] [PubMed] [Google Scholar]
  5. Baron B.W., Mittendorf R., Baron J.M. Presurgical plasma exchange for severe factor V deficiency. J Clin Apheresis. 2001;16:29–30. doi: 10.1002/jca.1005. [DOI] [PubMed] [Google Scholar]
  6. Bell W.R., Braine H.G., Ness P.M., Kickler T.S. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325:398–403. doi: 10.1056/NEJM199108083250605. [DOI] [PubMed] [Google Scholar]
  7. Bocanegra M., Bazan A.A., Velarde N.Z., Carpio M. Clinical evaluation of the administration of large volumes of plasma in the treatment of severely burned children. Surgery. 1978;83:558–563. [PubMed] [Google Scholar]
  8. Bolton-Maggs P.H., Perry D.J., Chalmers E.A., et al. The rare coagulation disorders — review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia. 2004;10:593–628. doi: 10.1111/j.1365-2516.2004.00944.x. [DOI] [PubMed] [Google Scholar]
  9. Bolton-Maggs P.H.B., Colvin B.T., Satchi G., Lee C.A., Lucas G.S. Thrombogenic potential of factor XI concentrate. Lancet. 1994;344:748–749. doi: 10.1016/S0140-6736(94)92237-3. [DOI] [PubMed] [Google Scholar]
  10. Borgman M.A., et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma. 2007;63:805–813. doi: 10.1097/TA.0b013e3181271ba3. [DOI] [PubMed] [Google Scholar]
  11. Bux J., Sachs U.J. The pathogenesis of transfusion-related acute lung injury (TRALI) Brit J Haematol. 2007;136:788–799. doi: 10.1111/j.1365-2141.2007.06492.x. [DOI] [PubMed] [Google Scholar]
  12. Cardigan R., Allford S., Williamson L. Levels of von Willebrand factor-cleaving protease are normal in methylene blue-treated freshfrozen plasma. Br J Haematol. 2002;117:253–254. doi: 10.1046/j.1365-2141.2002.3406_6.x. [DOI] [PubMed] [Google Scholar]
  13. Casbard A.C., Williamson L.M., Murphy M.F., Rege K., Johnson T. The role of prophylactic fresh frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. A systematic review. Anaesthesia. 2004;59:550–558. doi: 10.1111/j.1365-2044.2004.03711.x. [DOI] [PubMed] [Google Scholar]
  14. Caturelli E., Squillante M.M., Andriulli A., et al. Fine-needle liver biopsy in patients with severely impaired coagulation. Liver. 1993;13:270–273. doi: 10.1111/j.1600-0676.1993.tb00643.x. [DOI] [PubMed] [Google Scholar]
  15. Chekrizova V., Murphy W.G. Solvent-detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med. 2006;16:85–91. doi: 10.1111/j.1365-3148.2006.00626.x. [DOI] [PubMed] [Google Scholar]
  16. De la Rubia J., Arriaga F., Linares D., et al. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Brit J Haematol. 2001;114:721–723. doi: 10.1046/j.1365-2141.2001.02991.x. [DOI] [PubMed] [Google Scholar]
  17. Deorari A.K., Paul V.K., Shreshta L., Singh M. Symptomatic neonatal polycythemia: comparison of partial exchange transfusion with saline versus plasma. Ind Pediatr. 1995;32:1167–1171. [PubMed] [Google Scholar]
  18. Dupont J., Massiant F., Declerck N., et al. Liver transplantation without the use of fresh frozen plasma. Anesth Analg. 1996;83:681–686. doi: 10.1097/00000539-199610000-00004. [DOI] [PubMed] [Google Scholar]
  19. Erber W.N., Perry D.J. Plasma and plasma products in the treatment of massive haemorrhage. Best Pract Res Clin Haematol. 2006;19:97–112. doi: 10.1016/j.beha.2005.01.026. [DOI] [PubMed] [Google Scholar]
  20. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci. 1981;26:388–393. doi: 10.1007/BF01313579. [DOI] [PubMed] [Google Scholar]
  21. Faringer P.D., Mullins R.J., Johnson R.L., Trunkey D.D. Blood Component supplementation during massive transfusion of AS-1 red cells in trauma patients. J Trauma. 1993;34:481–487. doi: 10.1097/00005373-199304000-00002. [DOI] [PubMed] [Google Scholar]
  22. Favier R., Aoki N., de Moerloose P. Congenital α2-plasmin inhibitor deficiency: a review. Brit J Haematol. 2001;114:4–10. doi: 10.1046/j.1365-2141.2001.02845.x. [DOI] [PubMed] [Google Scholar]
  23. Fisher N.C., Mutimer D.J. Central venous cannulation in patients with liver disease and coagulopathy — a prospective audit. Crit Care Med. 1999;25:481–485. doi: 10.1007/s001340050884. [DOI] [PubMed] [Google Scholar]
  24. Fontana S., Kremer Hovinga J.A., Lämmle B., Mansouri Taleghani B. Treatment of thrombotic thrombocytopenic purpura. Vox Sang. 2006;90:245–254. doi: 10.1111/j.1423-0410.2006.00747.x. [DOI] [PubMed] [Google Scholar]
  25. Friedman L.S. The risk of surgery in patients with liver disease. Hepatology. 1999;29:1617–1623. doi: 10.1002/hep.510290639. [DOI] [PubMed] [Google Scholar]
  26. Furlan M., Robles R., Morselli B., Sandoz P., Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 1999;81:8–13. [PubMed] [Google Scholar]
  27. Gazzard B.G., Henderson J.M., Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut. 1975;16:617–620. doi: 10.1136/gut.16.8.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Gistad C.W. Anaphylactic transfusion reactions. Curr Opin Hematol. 2004;10:419–423. doi: 10.1097/00062752-200311000-00004. [DOI] [PubMed] [Google Scholar]
  29. Gonzalez-Boullosa R., Ocampo-Martinez R., Alarcon-Martin M.J., et al. The use of recombinant coagulation factor VII during haemarthroses and synovectomy in a patient with congenital factor V deficiency. Haemophilia. 2005;11:167–170. doi: 10.1111/j.1365-2516.2005.00956.x. [DOI] [PubMed] [Google Scholar]
  30. Greinacher A., Kiefel V., Klüter H., et al. Empfehlungen zur Thrombozytentransfusion der Thrombozyten-Arbeitsgruppe der DGTI, GTH und DGHO. Transfus Med Hemother. 2007;33:528–543. doi: 10.1159/000096293. [DOI] [PubMed] [Google Scholar]
  31. Gross S.J., Filston H.C., Anderson J.C. Controlled study of treatment for disseminated intravascular coagulation in the neonate. J Pediatr. 1982;100:445–448. doi: 10.1016/S0022-3476(82)80457-5. [DOI] [PubMed] [Google Scholar]
  32. Hardy J.F., de Moerloose P., Samama C.M. The coagulopathy of massive transfusion. Vox Sang. 2005;89:123–127. doi: 10.1111/j.1423-0410.2005.00678.x. [DOI] [PubMed] [Google Scholar]
  33. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol. 2004;11:346–350. doi: 10.1097/01.moh.0000137915.88478.23. [DOI] [PubMed] [Google Scholar]
  34. Hellstern P., Haubelt H. Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res 2002. 2002;107(suppl 1):S3–S8. doi: 10.1016/S0049-3848(02)00145-7. [DOI] [PubMed] [Google Scholar]
  35. Hellstern P., Sachse H., Schwinn H., Oberfrank K. Manufacture and in vitro characterization of solvent/detergent-treated human plasma. Vox Sang. 1992;63:178–185. doi: 10.1111/j.1423-0410.1992.tb05097.x. [DOI] [PubMed] [Google Scholar]
  36. Hiippala S. Replacement of massive blood loss. Vox Sang. 1998;74(suppl 2):399–407. doi: 10.1111/j.1423-0410.1998.tb05449.x. [DOI] [PubMed] [Google Scholar]
  37. Hiippala S.T., Myllylahtera E.M. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg. 1995;81:360–365. doi: 10.1097/00000539-199508000-00026. [DOI] [PubMed] [Google Scholar]
  38. Johansson P.I., et al. Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion. 2007;47:593–598. doi: 10.1111/j.1537-2995.2007.01160.x. [DOI] [PubMed] [Google Scholar]
  39. Kovacs M. International normalised ratio and liver impairment. The Lancet. 2002;359:695. doi: 10.1016/S0140-6736(02)08568-9. [DOI] [PubMed] [Google Scholar]
  40. Kujovich J.L. Hemostatic defects in end stage liver disease. Crit Care Med. 2005;21:563–587. doi: 10.1016/j.ccc.2005.03.002. [DOI] [PubMed] [Google Scholar]
  41. Leese T., Holliday M., Watkins M., et al. A multicentre controlled trial of high-volume fresh frozen plasma therapy in prognostically severe acute pancreatitis. Ann R Coll Surg Engl. 2001;73:207–214. [PMC free article] [PubMed] [Google Scholar]
  42. Leese T., Holliday M., Heath D., Hall A.W., Bell P.R. Multicentre clinical trial of low volume fresh frozen plasma therapy in acute pancreatitis. Brit J Surg. 1987;74:907–911. doi: 10.1002/bjs.1800741012. [DOI] [PubMed] [Google Scholar]
  43. Loirat C., Sonsino E., Hinglais N., et al. Treatment of the childhood haemolytic uraemic syndrome with plasma. Pediatr Nephrol. 1988;2:279–285. doi: 10.1007/BF00858677. [DOI] [PubMed] [Google Scholar]
  44. Martin R.C., 2nd, Jarnagin W.R., Fong Y., et al. The use of fresh frozen plasma after major hepatic resection for colorectal metastasis: is there a standard for transfusion? J Am Coll Surg. 2003;196:402–409. doi: 10.1016/S1072-7515(02)01752-0. [DOI] [PubMed] [Google Scholar]
  45. Matsushita T., Saito H. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No, but they need a careful look. J Thromb Haemost. 2006;4:721–723. doi: 10.1111/j.1538-7836.2006.02103.x. [DOI] [PubMed] [Google Scholar]
  46. McCall M.M., Blackwell M.M., Smyre J.T., et al. Fresh frozen plasma in the pediatric pump prime: a prospective, randomized trial. Ann Thorac Surg. 2004;77:983–987. doi: 10.1016/j.athoracsur.2003.09.030. [DOI] [PubMed] [Google Scholar]
  47. McVay P.A., Toy P.T.C.Y. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion. 1991;31:164–171. doi: 10.1046/j.1537-2995.1991.31291142949.x. [DOI] [PubMed] [Google Scholar]
  48. McVay P.A., Toy P.T.C.Y. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol. 1990;94:747–753. doi: 10.1093/ajcp/94.6.747. [DOI] [PubMed] [Google Scholar]
  49. Mintz P.D., Neff A., MacKenzie M., et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion. 2006;46:1693–1704. doi: 10.1111/j.1537-2995.2006.00959.x. [DOI] [PubMed] [Google Scholar]
  50. Mueller M.M., Bomke B., Seifried E. Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver disease. Thromb Res. 2002;107:S9–S17. doi: 10.1016/S0049-3848(02)00146-9. [DOI] [PubMed] [Google Scholar]
  51. Murray D.J., Pennell B.J., Weinstein S.L., Olson J.D. Packed red cells in acute blood loss: dilutional coagulopathy as a cause of surgical bleeding. Anesth Analg. 1995;81:360–365. doi: 10.1097/00000539-199512000-00038. [DOI] [PubMed] [Google Scholar]
  52. Murray D.J., Olsson J., Strauss R., Tinker J.H. Coagulation changes during packed red cell replacement of major blood loss. Anesthesiology. 1988;69:839–845. doi: 10.1097/00000542-198809010-00839. [DOI] [PubMed] [Google Scholar]
  53. Novakova I.R., van Ginneken C.A., Verbruggen H.W., Haaenen C. Factor XI kinetics after plasma exchange in severe factor XI deficiency. Haemostasis. 1986;16:51–56. doi: 10.1159/000215269. [DOI] [PubMed] [Google Scholar]
  54. O’Connell N.M. Factor XI deficiency. Semin Hematol. 2004;41:76–81. doi: 10.1053/j.seminhematol.2003.11.015. [DOI] [PubMed] [Google Scholar]
  55. Oliver W.C., Beynen F.M., Nuittall G.A., et al. Blood loss in infants and children for open heart operations: albumin 5% versus fresh-frozen plasma in the prime. Ann Thorac Surg. 2003;75:1506–1512. doi: 10.1016/S0003-4975(02)04991-3. [DOI] [PubMed] [Google Scholar]
  56. Osborn DA, Evans N (2004) Early volume expansion for prevention of morbidity and mortality in very preterm infants. Cochrane Database Syst Rev 2: CD002005 [DOI] [PMC free article] [PubMed]
  57. Ozier Y., Pessione F., Samain E., Courtois F. Institutional variability in transfusion practice for liver transplantation. Anesth Analg. 2003;97:671–679. doi: 10.1213/01.ANE.0000073354.38695.7C. [DOI] [PubMed] [Google Scholar]
  58. Pereira A. Methylene-blue-photoinactivated plasma and its contribution to blood safety. Transfusion. 2004;44:948–949. doi: 10.1111/j.0041-1132.2004.359_6.x. [DOI] [PubMed] [Google Scholar]
  59. Raphael JC, Chevret S, Hughes RAC, Annane D (2004) Plasma exchange for Guillain-Barre syndrome (Cochrane review). The Cochrane Library, Issue 2
  60. Reverter J.C. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? Yes. J Thromb Haemost. 2006;4:717–720. doi: 10.1111/j.1538-7836.2006.01887.x. [DOI] [PubMed] [Google Scholar]
  61. Rizzoni G., Claris-Appiani A., Edefonti A., et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr. 1988;112:284–290. doi: 10.1016/S0022-3476(88)80071-4. [DOI] [PubMed] [Google Scholar]
  62. Robert A., Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology. 1996;24:1392–1394. doi: 10.1002/hep.510240613. [DOI] [PubMed] [Google Scholar]
  63. Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis Study Group. N Engl J Med. 1991;325:393–397. doi: 10.1056/NEJM199108083250604. [DOI] [PubMed] [Google Scholar]
  64. Runkel S., Haubelt H., Hitzler W., Hellstern P. The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood. Transfusion. 2005;45:427–432. doi: 10.1111/j.1537-2995.2005.04276.x. [DOI] [PubMed] [Google Scholar]
  65. Sachs U.J., Kauschat D., Bein G. White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. Transfusion. 2005;45:1628–1631. doi: 10.1111/j.1537-2995.2005.00587.x. [DOI] [PubMed] [Google Scholar]
  66. Santagostino E., Mancuso M.E., Morfini M., et al. Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica. 2006;91:634–639. [PubMed] [Google Scholar]
  67. Schiff J., Misra M., Rendon G., Rothschild J., Schwaitzberg S. Laparoscopic cholecystectomy in cirrhotic patients. Surg Endosc. 2005;19:1278–1281. doi: 10.1007/s00464-004-8823-z. [DOI] [PubMed] [Google Scholar]
  68. Shepard K.V., Bukowski R.M. The treatment of thrombotic thrombocytopenic purpura with exchange transfusions, plasma infusions, and plasma exchange. Semin Hematol. 1987;24:178–193. [PubMed] [Google Scholar]
  69. Singh Y., Sawyer L.S., Pinkoski L.S., et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion. 2006;46:1168–1177. doi: 10.1111/j.1537-2995.2006.00867.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Solheim B.G. Universal pathogen-reduced plasma in elective open-heart surgery and liver resection. Clin Med Res. 2006;4:207–217. doi: 10.3121/cmr.4.3.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Supapannachart S., Siripoonya P., Boonwattanasoontorn W., Kanjanavanit S. Neonatal polycythemia: effects of partial exchange transfusion using fresh frozen plasma, hemaccel and normal saline. J Med Ass Thail. 1999;82(suppl 1):82–85. [PubMed] [Google Scholar]
  72. Tripodi A., Salerno F., Chantarangkul V., et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005;41:553–558. doi: 10.1002/hep.20569. [DOI] [PubMed] [Google Scholar]
  73. Williamson L.M., Cardigan R., Prowse C.V. Methylene blue-treaated fresh-frozen plasma: what is its contribution to blood safety? Transfusion. 2003;43:1322–1329. doi: 10.1046/j.1537-2995.2003.00483.x. [DOI] [PubMed] [Google Scholar]
  74. Yarranton H., Lawrie A.S., Purdy G., Mackie I.J., Machin S.J. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic Purpura. Transfus Med. 2004;14:39–44. doi: 10.1111/j.0958-7578.2004.00478.x. [DOI] [PubMed] [Google Scholar]
  75. Youssef W.I., Salazar F., Dasaranthy S., Beddow T., Mullen K.G. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol. 2003;98:1391–1394. doi: 10.1111/j.1572-0241.2003.07467.x. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Aledort L.M., Haschmeyer R., Petterson H., the Orthopaedic Outcome Study Group A longitudinal study of orthopaedic outcomes for severe factor VIII-deficient haemophiliacs. J Intern Med. 1994;236:391–399. doi: 10.1111/j.1365-2796.1994.tb00815.x. [DOI] [PubMed] [Google Scholar]
  2. Anwar R., Miloszewski K.J.A. Factor XIII deficiency. Brit J Haematol. 1999;107:468–484. doi: 10.1046/j.1365-2141.1999.01648.x. [DOI] [PubMed] [Google Scholar]
  3. Astermark J., Morado M., Rocino A., et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia. 2006;12:363–371. doi: 10.1111/j.1365-2516.2006.01296.x. [DOI] [PubMed] [Google Scholar]
  4. Berntorp E. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3. Semin Thromb Hemost. 2006;32:621–625. doi: 10.1055/s-2006-949667. [DOI] [PubMed] [Google Scholar]
  5. Blome M., Isgro F., Kiessling A.H., et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost. 2005;93:1101–1107. doi: 10.1160/TH04-12-0799. [DOI] [PubMed] [Google Scholar]
  6. Bolton-Maggs P.H.B., Perry D.J., Chalmers E.A., et al. The rare coagulation disorders — review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia. 2004;10:593–628. doi: 10.1111/j.1365-2516.2004.00944.x. [DOI] [PubMed] [Google Scholar]
  7. Bolton-Maggs P.H., Wensley R.T., Kernoff P.B.A., et al. Production and therapeutic use of a factor XI concentrate from plasma. Thromb Haemost. 1992;67:314–319. [PubMed] [Google Scholar]
  8. Brackmann H.H., Gormsen J. Massive factor VIII infusion in haemophilic patients with factor VIII inhibitor, high responder. Lancet. 1977;2:933. doi: 10.1016/S0140-6736(77)90871-6. [DOI] [PubMed] [Google Scholar]
  9. Bregenzer N., Caesar I., Andus T., et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Z Gastroenterol. 1999;37:999–1004. [PubMed] [Google Scholar]
  10. Bryant B.J., Klein H.G. Pathogen inactivation. The definitive safeguard for the blood supply. Arch Pathol Lab Med. 2007;131:719–733. doi: 10.5858/2007-131-719-PITDSF. [DOI] [PubMed] [Google Scholar]
  11. Burnouf T. Modern plasma fractionation. Transfus Med Rev. 2007;21:101–117. doi: 10.1016/j.tmrv.2006.11.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Burnouf T., Padilla A. Current strategies to prevent transmission of prions by human plasma derivatives. Transfus Clin Biol. 2006;13:320–328. doi: 10.1016/j.tracli.2006.11.001. [DOI] [PubMed] [Google Scholar]
  13. Burnouf-Radosevich M., Burnouf T. A therapeutic highly purified factor XI concentrate from human plasma. Transfusion. 1992;32:861–856. doi: 10.1046/j.1537-2995.1992.32993110761.x. [DOI] [PubMed] [Google Scholar]
  14. Canonico S. The use of human fibrin glue in the surgical operations. Acta Bio Medica. 2003;74(Suppl 2):21–25. [PubMed] [Google Scholar]
  15. Carcao M.D., Aledort L. Prophylactic factor replacement in hemophilia. Blood Rev. 2004;18:101–113. doi: 10.1016/S0268-960X(03)00038-9. [DOI] [PubMed] [Google Scholar]
  16. Chandler W.L., Patel M.A., Gravelle L., et al. Factor XIIIa and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2001;12:101–108. doi: 10.1097/00001721-200103000-00003. [DOI] [PubMed] [Google Scholar]
  17. Cohn E.J., Oncley J.L., Strong L.E., Hughes W.L., Armstrong S.H. Chemical, clinical and immunological studies on the products of human plasma fractionation. I. The characterization of the protein fractions of human plasma. J Clin Invest. 1944;23:417–432. doi: 10.1172/JCI101508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Desmesmay K., Tissot E., Bulabois C.E., et al. Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases. Transplantation. 2002;74:1190–1192. doi: 10.1097/00007890-200210270-00024. [DOI] [PubMed] [Google Scholar]
  19. Egbring R., Seitz R., Gürten G.V., et al. et al. Bleeding complicatins in heterozygotes with congenital factor XIII deficiency. In: Mossesson M.E., et al.et al., editors. Fibrinogen 3. Biochemistry, biological functions, gene regulation and expression. Amsterdam: Elsevier; 1988. pp. 341–346. [Google Scholar]
  20. Ettingshausen C.E., Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia. 2006;12(Suppl 6):102–106. doi: 10.1111/j.1365-2516.2006.01373.x. [DOI] [PubMed] [Google Scholar]
  21. Fischer K., van der Bom J.G., Molho G., et al. Prophylactic versus ondemand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia. 2002;8:745–752. doi: 10.1046/j.1365-2516.2002.00695.x. [DOI] [PubMed] [Google Scholar]
  22. Gazzard BG, Henderson JM, Williams R (1975) The use of fresh frozen plasma or a concentrate of factor IX as replacement therapy before liver biopsy. Gut 621–625 [DOI] [PMC free article] [PubMed]
  23. Greinacher A., Kiefel V., Klüter H., Kroll H., Pötzsch B., Riess H. Empfehlungen zur Thrombozytentransfusion der Thrombozyten-Arbeitsgruppe der DGTI, GTH und DGHO. Transfus Med Hemother. 2006;33:528–543. doi: 10.1159/000096293. [DOI] [PubMed] [Google Scholar]
  24. Gringeri A., Mannucci P.M., Italian Association of Haemophilia Centres Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia. 2005;11:611–619. doi: 10.1111/j.1365-2516.2005.01161.x. [DOI] [PubMed] [Google Scholar]
  25. Gödje O., Gallmeier U., Schelian M., Grünewald M., Mair H. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg. 2005;54:26–33. doi: 10.1055/s-2005-872853. [DOI] [PubMed] [Google Scholar]
  26. Gödje O., Haushofer M., Lamm P., Reichart B. The effect of factor XIII on bleeding in coronary surgery. Thorac Cardiovasc Surg. 1998;46:263–267. doi: 10.1055/s-2007-1010236. [DOI] [PubMed] [Google Scholar]
  27. Gouw S.C., van der Bom J.G., Marijke van den Berg H. Treatmentrelated risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109:4648–4654. doi: 10.1182/blood-2006-11-056291. [DOI] [PubMed] [Google Scholar]
  28. Gouw S.C., van der Bom J.G., Auerswald G., et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood. 2007;109:4693–4697. doi: 10.1182/blood-2006-11-056317. [DOI] [PubMed] [Google Scholar]
  29. Hellstern P., Halbmayer W.M., Köhler M., Seitz R., Müller-Berghaus G. Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res. 1999;95(Suppl 1):S3–S6. doi: 10.1016/S0049-3848(99)00077-8. [DOI] [PubMed] [Google Scholar]
  30. Hoots W.K., Nugent D.J. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost. 2006;96:433–440. doi: 10.1160/th06-02-0125. [DOI] [PubMed] [Google Scholar]
  31. Julien D., Souillet H.L., Faure M., Claudy A. Coagulation factor XIII in scleroderma. Eur J Dermatol. 1998;8:231–234. [PubMed] [Google Scholar]
  32. Karges H.E., Metzner H.J. Therapeutic factor XIII preparations and perspectives for recombinant factor XIII. Semin Thromb Hemost. 1996;22:427–436. doi: 10.1055/s-2007-999042. [DOI] [PubMed] [Google Scholar]
  33. Kessler C.M. Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data? J Thromb Haemost. 2006;4:963–966. doi: 10.1111/j.1538-7836.2006.01944.x. [DOI] [PubMed] [Google Scholar]
  34. Kistler P., Nitschmann H. Large-scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang. 1962;7:414–424. doi: 10.1111/j.1423-0410.1962.tb03274.x. [DOI] [PubMed] [Google Scholar]
  35. Kouides P.A., Kulzer L. Prophylactic treatment of severe factor X deficiency with prothrombin complex concentrate. Haemophilia. 2001;7:220–223. doi: 10.1046/j.1365-2516.2001.00485.x. [DOI] [PubMed] [Google Scholar]
  36. Kreuz W., Meili E., Peter-Salonen K., et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apheresis Sci. 2005;32:247–253. doi: 10.1016/j.transci.2004.08.003. [DOI] [PubMed] [Google Scholar]
  37. Lankiewicz M.W., Hays J., Friedman K.D., Tinkoff G., Blatt P.M. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost. 2006;4:967–970. doi: 10.1111/j.1538-7836.2006.01815.x. [DOI] [PubMed] [Google Scholar]
  38. Lechler E. Use of prothrombin complex concentrates for prophylaxis and treatment of bleeding episodes in patients with hereditary deficiency of prothrombin, factor VII, factor X, protein C, protein S, or protein Z. Thromb Res. 1999;95(Suppl 1):S39–S50. doi: 10.1016/S0049-3848(99)00083-3. [DOI] [PubMed] [Google Scholar]
  39. Lobel J.S., Majumdar S., Kovats-Bell S. Successful prophylactic treatment for bleeding in a girl with severe hereditary prothrombin deficiency using a prothrombin complex concentrate (Bebulin® VH) J Pediatr Hematol Oncol. 2004;26:480–483. doi: 10.1097/01.mph.0000130220.33907.5a. [DOI] [PubMed] [Google Scholar]
  40. Lorenz R., Kienast R., Otto U., et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hapatol. 2003;15:15–20. doi: 10.1097/00042737-200301000-00004. [DOI] [PubMed] [Google Scholar]
  41. Lorenz R., Olbert P., Born P. Factor XIII in chronic inflammatory bowel disease. Sem Thromb Hemost. 1996;22:451–455. doi: 10.1055/s-2007-999045. [DOI] [PubMed] [Google Scholar]
  42. Manco-Johnson M.J., Abshire T.C., Shapiro A.D., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–544. doi: 10.1056/NEJMoa067659. [DOI] [PubMed] [Google Scholar]
  43. Mannucci P.M. Treatment of von Willebrand’s disease. N Engl J Med. 2004;351:683–694. doi: 10.1056/NEJMra040403. [DOI] [PubMed] [Google Scholar]
  44. Mannucci P.M., Franchi F., Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet. 1976;2:542–545. doi: 10.1016/S0140-6736(76)91794-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Michiels J.J., van Vliet H.H., Berneman Z., et al. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients with von Willebrand disease types 1, 2 and 3. Clin Appl Thromb Hemost. 2007;13:14–34. doi: 10.1177/1076029606296399. [DOI] [PubMed] [Google Scholar]
  46. Peyvandi F., Haertel S., Knaub S., Mannucci P.M. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia of hypofibrinogenemia. J Thromb Haemost. 2006;4:1634–1637. doi: 10.1111/j.1538-7836.2006.02014.x. [DOI] [PubMed] [Google Scholar]
  47. Plug I., van der Bom J.G., Peters M., et al. Thirty years of hemophilia treatment in the Netherlands, 1972–2001. Blood. 2004;104:3494–3500. doi: 10.1182/blood-2004-05-2008. [DOI] [PubMed] [Google Scholar]
  48. Poon M.C. Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opin Hematol. 2001;8:312–318. doi: 10.1097/00062752-200109000-00008. [DOI] [PubMed] [Google Scholar]
  49. Preston F.E., Laidlaw S.T., Sampson B., Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Brit J Haematol. 2002;116:619–624. doi: 10.1046/j.0007-1048.2001.03295.x. [DOI] [PubMed] [Google Scholar]
  50. Royal S., Schramm W., Berntorp E., et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia. 2002;8:44–50. doi: 10.1046/j.1365-2516.2002.00581.x. [DOI] [PubMed] [Google Scholar]
  51. Scharrer I. Leberzirrhose und Gerinnungsstörungen. Hämostaseologie. 2005;25:205–208. doi: 10.1267/hämo05020205. [DOI] [PubMed] [Google Scholar]
  52. Schexneider K.I. Fibrin sealants in surgical or traumatic hemorrhage. Curr Opin Hematol. 2004;11:232–326. doi: 10.1097/01.moh.0000142104.21058.df. [DOI] [PubMed] [Google Scholar]
  53. Schimpf K., Fischer B., Rothmann P. Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled study. Scand J Haematol Suppl. 1977;30:79–80. doi: 10.1111/j.1600-0609.1977.tb01528.x. [DOI] [PubMed] [Google Scholar]
  54. Schopgen G., Bonik K., Rosenkranz G. Fibrinogensubstitution mit Haemocomplettan HS. Hämostaseologie. 1994;14:140–148. [Google Scholar]
  55. Schramm W., Scharrer I. Konsensus Empfehlungen zur Hämophiliebehandlung in Deutschland. GTH Hämophiliekommission, update 1999. Hämophilieblätter. 2000;34:62–62. [Google Scholar]
  56. Spence R.K., Mintz P.D. Transfusion in trauma, surgery and critical care. In: Mintz P.D., editor. Transfusion therapy. Bethesda: AABB Press; 2005. pp. 203–241. [Google Scholar]
  57. Steen Carlsson K., Hojgard S., Glomstein A., et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia. 2003;9:555–566. doi: 10.1046/j.1365-2516.2003.00817.x. [DOI] [PubMed] [Google Scholar]
  58. Tengborn L., Berntorp E. Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia B. Haemophilia. 1998;4:56–59. doi: 10.1046/j.1365-2516.1998.00142.x. [DOI] [PubMed] [Google Scholar]
  59. Tosetto A., Rodeghiero F., Gatto E., Manotti C., Poli T. An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophophamide. Am J Hematol. 1995;48:34–39. doi: 10.1002/ajh.2830480107. [DOI] [PubMed] [Google Scholar]
  60. Van den Berg H.M., Fischer K., van der Bom J.G., Rosendaal G., Mauser-Bunschoten E.P. Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies. Haemophilia. 2002;8(Suppl 2):43–46. doi: 10.1046/j.1351-8216.2001.00120.x. [DOI] [PubMed] [Google Scholar]
  61. Venturi C., Zendri E., Santini M., et al. Sceredema of Buschke: remission with factor XIII treatment. Int J Tiissue React. 2004;26:25–28. [PubMed] [Google Scholar]
  62. Vigué B., Ract C., Tremey B., et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med. 2007;33:721–725. doi: 10.1007/s00134-007-0528-z. [DOI] [PubMed] [Google Scholar]
  63. Wettstein P., Haeberli A., Stutz M., et al. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth Analg. 2004;99:1564–1569. doi: 10.1213/01.ANE.0000134800.46276.21. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Abshire T., Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004;2:899–909. doi: 10.1111/j.1538-7836.2004.00759.x. [DOI] [PubMed] [Google Scholar]
  2. Ahonen J., Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth. 2005;94:592–595. doi: 10.1093/bja/aei094. [DOI] [PubMed] [Google Scholar]
  3. Aledort L.M. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. Thromb Haemost. 2004;2:1700–8. doi: 10.1111/j.1538-7836.2004.00944.x. [DOI] [PubMed] [Google Scholar]
  4. Almeida A.M., Khair K., Hann I., Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol. 2003;121:477–481. doi: 10.1046/j.1365-2141.2003.04286.x. [DOI] [PubMed] [Google Scholar]
  5. Astermark J., Donfield S.M., DiMichele D.M., Gringeri A., Gilbert S.A., Waters J., Berntorp E., FENOC Study Group A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109:546–51. doi: 10.1182/blood-2006-04-017988. [DOI] [PubMed] [Google Scholar]
  6. Berntorp E., Shapiro A., Astermark J., et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia. 2006;12(Suppl 6):1–7. doi: 10.1111/j.1365-2516.2006.01359.x. [DOI] [PubMed] [Google Scholar]
  7. Bijsterveld N.R., Moons A.H., Boekholdt S.M., van Aken B.E., Fennema H., Peters R.J., Buller H.R., Levi M. Ability of recombinant factor VIIa to ! reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106:2550–4. doi: 10.1161/01.CIR.0000038501.87442.02. [DOI] [PubMed] [Google Scholar]
  8. Boffard K.D., Riou B., Warren B., the NovoSeven Trauma Study Group et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8–15. doi: 10.1097/01.TA.0000171453.37949.B7. [DOI] [PubMed] [Google Scholar]
  9. Bui J.D., Despotis G.D., Trulock E.P., Patterson G.A., Goodnough L.T. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg. 2002;124:852–4. doi: 10.1067/mtc.2002.126038. [DOI] [PubMed] [Google Scholar]
  10. Chan S., Kong M., Minning D.M., Hedner U., Marder V.J. Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin. J Thromb Haemost. 2003;1:760–5. doi: 10.1046/j.1538-7836.2003.00101.x. [DOI] [PubMed] [Google Scholar]
  11. Diprose P., Herbertson M.J., O’Shaughnessy D., Gill R. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth. 2005;95:596–602. doi: 10.1093/bja/aei244. [DOI] [PubMed] [Google Scholar]
  12. Ekert H., Brizard C., Eyers R., Cochrane A., Henning R. Elective administration of low dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypasssurgery for congenital heart disease does not shorten time to chest closure or reduce blood loss or need for transfusions: a randomized, double-blind, parallel group, placebo controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic therapy. Blood Coagul Fibrinol. 2006;17:389–95. doi: 10.1097/01.mbc.0000233369.03358.c1. [DOI] [PubMed] [Google Scholar]
  13. Firozvi K., Deveras R.A., Kessler C.M. Reversal of low-molecularweight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. Am J Hematol. 2006;81:582–9. doi: 10.1002/ajh.20652. [DOI] [PubMed] [Google Scholar]
  14. Franchini M., Salvagno G.L., Lippi G. Inhibitors in mild/moderate haemophilia A: an update. Haemost. 2006;96:113–8. [PubMed] [Google Scholar]
  15. Girolami A., Randi M.L., Ruzzon E., Zanon E., Girolami B. Myocardial infarction, other arterial thrombosis and invasive coronary procedures, in hemaophilia B: a critical evaluation of reported cases. J Thromb Thrombolysis. 2005;20:43–6. doi: 10.1007/s11239-005-2227-3. [DOI] [PubMed] [Google Scholar]
  16. Hay C.R., Negrier C., Ludlam C.A. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost. 1997;78:1463–1467. [PubMed] [Google Scholar]
  17. Hedner U., Erhardtsen E. Potential role of for rhFVIIa in transfusion medicine. Transfusion. 2002;42:114–124. doi: 10.1046/j.1537-2995.2002.00017.x. [DOI] [PubMed] [Google Scholar]
  18. Hoffman M., Monroe D.M. A cell based model of hemostasis. Thromb Haemost. 2001;88:958–65. [PubMed] [Google Scholar]
  19. Hollnberger H., Gruber E., Seelbach-Goebel B. Major Post-Partum Hemorrhage and Treatment with Recombinant Factor VIIa. Anesth Analg. 2005;101:1186–1187. doi: 10.1213/01.ANE.0000180268.85925.78. [DOI] [PubMed] [Google Scholar]
  20. Huvers F., Slappendel R., Benraad B., van Hellemondt G., van Kraaij M. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Neth J Med. 2005;63:184–6. [PubMed] [Google Scholar]
  21. Ingerslev J., Knudsen L., Hvid I., Tange M.R., Fredberg U., Sneppen O. Use of recombinant factor VIIa in surgery in factor-VII-deficient patients. Haemophilia. 1997;3:215–18. doi: 10.1046/j.1365-2516.1997.00105.x. [DOI] [PubMed] [Google Scholar]
  22. Jurlander B., Thim L., Klausen N., et al. Recombinant activated factor VII (rhFVIIa): Characterisation, manufacturing and clinical development. Sem Thromb Haemost. 2001;27:373–383. doi: 10.1055/s-2001-16890. [DOI] [PubMed] [Google Scholar]
  23. Kavakli K., Makris M., Zulfikar B., Erhardtsen E., Abrams Z., Kenet G. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost. 2006;95:600–5. [PubMed] [Google Scholar]
  24. Karkouti K., Yau T.M., Riazi S., et al. Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. Can J Anaesth. 2006;53:802–9. doi: 10.1007/BF03022797. [DOI] [PubMed] [Google Scholar]
  25. Karkouti K., Beattie W.S., Wijeysundera D.N., et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion. 2005;45:26–34. doi: 10.1111/j.1537-2995.2005.04216.x. [DOI] [PubMed] [Google Scholar]
  26. Kenet G., Lubetzk A., Luboshitz J., Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven) J Thromb Haemost. 2003;1:450–455. doi: 10.1046/j.1538-7836.2003.00059.x. [DOI] [PubMed] [Google Scholar]
  27. Key N.S., Christie B., Henderson N., Nelsestuen G.L. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost. 2002;88:60–65. [PubMed] [Google Scholar]
  28. Leissinger C.A., Becton D.L., Ewing N.P., Valentino L.A. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia. 2007;13:249–55. doi: 10.1111/j.1365-2516.2007.01442.x. [DOI] [PubMed] [Google Scholar]
  29. Levy J.H., Fingerhut A., Brott T., Langbakke I.H., Erhardtsen E., Porte R.J. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhoise, or severe traumatic injury: review of safety profile. Transfusion. 2006;46:919–33. doi: 10.1111/j.1537-2995.2006.00824.x. [DOI] [PubMed] [Google Scholar]
  30. Lodge J.P., Jonas S., Jones R.M., et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl. 2005;11:973–9. doi: 10.1002/lt.20470. [DOI] [PubMed] [Google Scholar]
  31. Lodge J.P., Jonas S., Oussoultzoglu E., et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology. 2005;102:269–75. doi: 10.1097/00000542-200502000-00006. [DOI] [PubMed] [Google Scholar]
  32. Lusher J.M., Roberts H.R., Davignon G., Joist J.H., Smith H., Shapiro A., Laurian Y., Kasper C.K., Mannucci P.M. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4:790–798. doi: 10.1046/j.1365-2516.1998.00209.x. [DOI] [PubMed] [Google Scholar]
  33. Mayer S.A., Brun N.C., Begtrup K., Recombinant Activated Factor VII Intracerebral Hemorrhage Trial investigators et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777–85. doi: 10.1056/NEJMoa042991. [DOI] [PubMed] [Google Scholar]
  34. Moulton M.J., Creswell L.L., Mackey M.E., Cox J.L., Rosenbloom M. Reexploration for Bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg. 1996;111:1037–46. doi: 10.1016/S0022-5223(96)70380-X. [DOI] [PubMed] [Google Scholar]
  35. Ng H.J., Koh L.P., Lee L.H. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol. 2003;82:257–8. doi: 10.1007/s00277-003-0633-1. [DOI] [PubMed] [Google Scholar]
  36. Nurden A.T., George J.N. Inherited abnormalities of the platelet membrane: Glanzmann Thrombasthenia, Bernard-Soulier-Syndrome, and other disorders. In: Colman R., editor. Haemostsasis and Thrombosis. Philadelphia: Lippincott Williams & Wilkins; 2001. [Google Scholar]
  37. O’Connell K.A., Wood J.J., Wise R.P., Lozier J.N., Braun M.M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293–8. doi: 10.1001/jama.295.3.293. [DOI] [PubMed] [Google Scholar]
  38. Peerlinck K., Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor. Thromb Haemost. 1999;82:1775–6. [PubMed] [Google Scholar]
  39. Poon M.C. The evidence for the use of recombinant human activated factor vii in the treatment of bleeding patients with quantitative and qualitative platelet disorders. Transfus Med Rev. 2007;21:223–36. doi: 10.1016/j.tmrv.2007.03.003. [DOI] [PubMed] [Google Scholar]
  40. Romagnoli S., Bevilacqua S., Gelsomino S., Pradella S., Ghili L., Rostagno C., Gensini G.F., Sorbara C. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg. 2006;102:1320–6. doi: 10.1213/01.ane.0000209023.96418.e5. [DOI] [PubMed] [Google Scholar]
  41. Santagostino E., Mancuso M.E., Rocino A., Mancuso G., Scaraggi F., Mannucci P.M. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost. 2006;4:367–71. doi: 10.1111/j.1538-7836.2006.01772.x. [DOI] [PubMed] [Google Scholar]
  42. Scharrer I., Großmann R. Erworbene Hemmkörper-Hämophilie. Anästhesist. 2000;49:34–42. doi: 10.1007/s001010050007. [DOI] [Google Scholar]
  43. Schneiderman J., Rubin E., Nugent D.J., Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia. 2007;13:244–8. doi: 10.1111/j.1365-2516.2007.01451.x. [DOI] [PubMed] [Google Scholar]
  44. Shapiro A.D., Gilchrist G.S., Hoots W.K., Cooper H.A., Gastineau D.A. Prospective, randomised trial of two doses of rFVIIa (NovoSeven®) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80:773–778. [PubMed] [Google Scholar]
  45. Spahn D.R., Cerny V., Coats T.J., Task Force for Advanced Bleeding Care in Trauma et al. Management of bleeding following major trauma: a European guideline. Crit Care. 2007;11:R17. doi: 10.1186/cc5686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Stepinska J., Banaszewski M., Konopka A., Szajewski T. Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban. Thromb Haemost. 2002;87:355–6. [PubMed] [Google Scholar]
  47. Turecek P.L., Varadi K., Keil B., Negrier C., Berntorp E., Astermark J., Bordet J.C., Morfini M., Linari S., Schwarz H.P. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb. 2003;33:16–22. doi: 10.1159/000071637. [DOI] [PubMed] [Google Scholar]
  48. Villar A., Aronis S., Morfini M., Santagostino E., Auerswald G., Thomsen H.F., Erhardtsen E., Giangrande P.L.F. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia. 2004;10:352–359. doi: 10.1111/j.1365-2516.2004.00925.x. [DOI] [PubMed] [Google Scholar]
  49. Vincent J.L., Rossaint R., Riou B., Ozier Y., Zideman D., Spahn D.R. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding 73-a European perspective. Crit Care. 2006;10(4):R120. doi: 10.1186/cc5026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Virchis A., Hughes C., Berney S. Severe gastrointestinal hemorrhage responding to recombinant factor VIIa in a Jehovas witness with refractory immune thrombocytopenia. Haematology J. 2004;5:281–282. doi: 10.1038/sj.thj.6200395. [DOI] [PubMed] [Google Scholar]
  51. von Heymann C., Jonas S., Spies C., Wernecke K.D., Ziemer S., Janssen D., Koscielny J. Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data. Crit Care. 2008;12:R14. doi: 10.1186/cc6788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. von Heymann C., Redlich U., Jain U., et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery—a retrospective analysis of safety and efficacy. Crit Care Med. 2005;33:2241–6. doi: 10.1097/01.CCM.0000181527.47749.57. [DOI] [PubMed] [Google Scholar]
  53. Vorstand und wissenschaftlicher Beirat der Bundesärztekamme, editor. Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. 3. überarbeitete Aufl. Köln: Deutscher Ärzte-Verlag; 2003. p. 134. [Google Scholar]
  54. Young G., Shafer F.E., Rojas P., Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg (−1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia. 2008;14:287–94. doi: 10.1111/j.1365-2516.2007.01601.x. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Anderson N.A., Gray S., Copplestone J.A., et al. A prospectice randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Transfus Med. 1996;6:33–39. doi: 10.1046/j.1365-3148.1997.d01-73.x. [DOI] [PubMed] [Google Scholar]
  2. Andreu G., Morel P., Forestier F., Debeir J., Rebibo D., Janvier G., Hervé P. Hemovigilance netork in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion. 2002;42:1356–1364. doi: 10.1046/j.1537-2995.2002.00202.x. [DOI] [PubMed] [Google Scholar]
  3. Arnold D.M., Heddle N. M., Kulczycky M., Carruthers J., Sigouin C., Blajchman M.A. In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers. Transfusion. 2006;46:257–264. doi: 10.1111/j.1537-2995.2006.00709.x. [DOI] [PubMed] [Google Scholar]
  4. Beilin Y., Zahn J., Comerford M. Safe epidural analgesia in thirty patients with platelet counts between 69,000 and 98,000 mm(-3) Anesth Analg. 1997;85:385–388. doi: 10.1097/00000539-199708000-00025. [DOI] [PubMed] [Google Scholar]
  5. Benjamin R.J., Antin J.H. ABO incompatible bone marrow transplantation: the transfuson of incompatible plasma my exacerbate regimen-related toxicity. Transfusion. 1999;39:1273–4. doi: 10.1046/j.1537-2995.1999.39111273.x. [DOI] [PubMed] [Google Scholar]
  6. Benjamin R.J., Mcgurk S., Ralston M.S., et al. AB0 incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion. 1999;39:179–87. doi: 10.1046/j.1537-2995.1999.39299154733.x. [DOI] [PubMed] [Google Scholar]
  7. Bierling P., Fromont P., Bettaieb A., Duedari N. Anti-Br(a) antibodies in the French population [letter] Br J Haematol. 1989;73:428–429. doi: 10.1111/j.1365-2141.1989.tb07771.x. [DOI] [PubMed] [Google Scholar]
  8. Blumberg N., Heal J.M., Hick G.L., et al. Association of AB0-mismatched platelet transfusions with morbidity and mortality in cardiac surgery. Transfusion. 2001;41:790–3. doi: 10.1046/j.1537-2995.2001.41060790.x. [DOI] [PubMed] [Google Scholar]
  9. Bravo A.A., Sheth S.G., Chopra S. Liver biopsy. N Engl J Med. 2001;344:495–500. doi: 10.1056/NEJM200102153440706. [DOI] [PubMed] [Google Scholar]
  10. Bux J., Becker F., Seeger W., Kilpatrick D., Chatman J., Waters A. Transfusion related acute lung injury due to HLA-A2-specific antibodies in recipient and NB1-specific antibodies in donor blood. Br J Heamatol. 1996;93:707–71. doi: 10.1046/j.1365-2141.1996.d01-1703.x. [DOI] [PubMed] [Google Scholar]
  11. Contreras M. Final statement from the consensus conference on platelet transfusion. Transfusion. 1998;38:796–797. doi: 10.1046/j.1537-2995.1998.38898375520.x. [DOI] [PubMed] [Google Scholar]
  12. Delaflor-Weiss E., Mintz P.D. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev. 2000;14:180–196. doi: 10.1016/S0887-7963(00)80007-3. [DOI] [PubMed] [Google Scholar]
  13. Duquesnoy R.J., Anderson A.J., Tomasulo P.A., et al. AB0 compatibility and platelet transfusions of alloimmunized thrombocytopenic patients. Blood. 1979;54:595–9. [PubMed] [Google Scholar]
  14. Edelson R.N., Chernik N.L., Posner J.B. Spinal subdural hematomas complicating lumbar puncture. Arch Neurol. 1974;31:134–137. doi: 10.1001/archneur.1974.00490380082011. [DOI] [PubMed] [Google Scholar]
  15. Gelb A.B., Leavitt A.D. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Transfusion. 1997;37:624–630. doi: 10.1046/j.1537-2995.1997.37697335157.x. [DOI] [PubMed] [Google Scholar]
  16. Godeau B., Chevret S., Varet B., rench ATIP Study Group et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet. 2002;359:23–9. doi: 10.1016/S0140-6736(02)07275-6. [DOI] [PubMed] [Google Scholar]
  17. Greinacher A., Kiefel V., Klüter H., Kroll H., Pötzsch B., Riess H. Empfehlungen zur Thrombozytentransfusion der Thrombozyten-Arbeitsgruppe der DGTI, GTH und DGHO. Transfus Med Hemoth. 2006;33:528–543. doi: 10.1159/000096293. [DOI] [PubMed] [Google Scholar]
  18. Heal J.M., Blumberg N., Masel D. An evaluation of crossmatching, HLA, and AB0 matching for platelet transfusions to refractory patients. Blood. 1987;70:23–30. [PubMed] [Google Scholar]
  19. Heal J.M., Blumberg N. Optimizing platelet transfusion therapy. Blood. 2004;18(3):149–65. doi: 10.1016/S0268-960X(03)00057-2. [DOI] [PubMed] [Google Scholar]
  20. Heal J.M., Masel D., Rowe J.M., et al. Circulating immune complexes involving the AB0 system after platelet transfusion. Br J Haematol. 1993;85:566–572. doi: 10.1111/j.1365-2141.1993.tb03349.x. [DOI] [PubMed] [Google Scholar]
  21. Heal J.M., Rowe J.M., Blumberg N. AB0 and platelet transfusion revisited. Ann Hematol. 1993;66:309–14. doi: 10.1007/BF01695973. [DOI] [PubMed] [Google Scholar]
  22. Heckman K.D., Weiner G.J., Davis C.S., Strauss R.G., Jones M.P., Burns C.P. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol. 1997;15:1143–9. doi: 10.1200/JCO.1997.15.3.1143. [DOI] [PubMed] [Google Scholar]
  23. Heddle N.M., Blajchman M.A., Meyer R.M., et al. A randomised controlled trial comparing the frequency of acute reactions to plasmaremoved platelets and prestorage WBC-reduced platelets. Transfusion. 2002;42:556–566. doi: 10.1046/j.1537-2995.2002.00094.x. [DOI] [PubMed] [Google Scholar]
  24. Hew-Wing P., Rolbin S.H., Hew E., Amato D. Epidural anaesthesia and thrombocytopenia. Anesthesia. 1989;44:775–777. doi: 10.1111/j.1365-2044.1989.tb09270.x. [DOI] [PubMed] [Google Scholar]
  25. Holness L., Knippen M.A., Simmons L., Lachenbruch P.A. Fatalities caused by TRALI. Transfus Med Rev. 2004;18:184–188. doi: 10.1016/j.tmrv.2004.03.004. [DOI] [PubMed] [Google Scholar]
  26. Howard J.E., Perkins H.A. The natural history of alloimmunization to platelets. Transfusion. 1978;18:496–503. doi: 10.1046/j.1537-2995.1978.18478251250.x. [DOI] [PubMed] [Google Scholar]
  27. Kickler T., Braine H., Piantadosi S., Ness P.M., Herman J.H., Rothko K. A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombcytopenic patients. Blood. 1990;75:313–316. [PubMed] [Google Scholar]
  28. Kiefel V., Bassler D., Kroll H., et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT) Blood. 2006;107:3761–3763. doi: 10.1182/blood-2005-06-2235. [DOI] [PubMed] [Google Scholar]
  29. Kiefel V., König C., Kroll H., Santoso S. Platelet alloantibodies in transfused patients. Transfusion. 2001;41:766–770. doi: 10.1046/j.1537-2995.2001.41060766.x. [DOI] [PubMed] [Google Scholar]
  30. Klumpp T.R., Herman J.H., Innis S., et al. Factors associated with response to platelet transfusions following hematopoietic stem cell transplantation. Bone Marrow Transplant. 1996;17:1035–41. [PubMed] [Google Scholar]
  31. Klüter H., Bubel S., Kirchner H., Wilhelm D. Febrile and allergic transfusion reactions after transfusion of white cell-poor platelet preparations. Transfusion. 1999;39:1179–83. doi: 10.1046/j.1537-2995.1999.39111179.x. [DOI] [PubMed] [Google Scholar]
  32. Klüter H., Dörges I., Maass E., Wagner T., Bartels H., Kirchner H. In-vivo evaluation of random donor platelet concentrates from pooled buffy coats. Ann Hematol. 1996;73:85–89. doi: 10.1007/s002770050206. [DOI] [PubMed] [Google Scholar]
  33. Kroll H., Carl B., Santoso S., Bux J., Bein G. Workshop report on the genotyping of blood cell alloantigens. Transfusion Medicine. 2001;11:211–219. doi: 10.1046/j.1365-3148.2001.00307.x. [DOI] [PubMed] [Google Scholar]
  34. Kroll H., Kiefel V., Santoso S. Clinical aspects and typing of platelet alloantigens. Vox Sanguinis. 1998;74:345–354. doi: 10.1111/j.1423-0410.1998.tb05441.x. [DOI] [PubMed] [Google Scholar]
  35. Kroll H., Kiefel V., Giers G., Bald R., Hoch J., Hanfland P., Hansmann M., Mueller-Eckhardt C. Maternal intravenous immunoglobulin treatment does not prevent intracranial haemorrhage in fetal alloimmune thrombocytopenia. Transfusion Medicine. 1994;4:293–296. doi: 10.1111/j.1365-3148.1994.tb00266.x. [DOI] [PubMed] [Google Scholar]
  36. Kroll H., Yates J., Santoso S. Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens. Transfusion. 2005;45:353–8. doi: 10.1111/j.1537-2995.2005.04218.x. [DOI] [PubMed] [Google Scholar]
  37. Langenscheidt F., Kiefel V., Santoso S., Mueller-Eckhardt C. Platelet transfusion refractoriness associated with two rare platelet-specific alloantibodies (anti-Bak(a) and anti-Pl(A2)) and multiple HLA-antibodies. Transfusion. 1988;28:597–600. doi: 10.1046/j.1537-2995.1988.28689059040.x. [DOI] [PubMed] [Google Scholar]
  38. Lawrence J.B., Yomtovian R.A., Hammons T., Masarik S.R., Chongkolwatana V., Creger R.J., Manka A., Lazarus H.M. Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leuk Lymphoma. 2001;41:67–76. doi: 10.3109/10428190109057955. [DOI] [PubMed] [Google Scholar]
  39. Lee E.J., Schiffer C.A. AB0 incompatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion. 1989;29:384–389. doi: 10.1046/j.1537-2995.1989.29589284135.x. [DOI] [PubMed] [Google Scholar]
  40. Lee E.J., Norris D., Schiffer C.A. Intravenous immune globulin for patients alloimmunized to random donor platelet transfusion. Transfusion. 1987;27:245–247. doi: 10.1046/j.1537-2995.1987.27387235630.x. [DOI] [PubMed] [Google Scholar]
  41. Lin Y., Callum J.L., Coovadia A.S., Murphy P.M. Transfusion of AB0 non identiccal platelets is not associated with adverse clinical outcomes in cardiovascular surgery patients. Transfusion. 2002;42:166–72. doi: 10.1046/j.1537-2995.2002.00037.x. [DOI] [PubMed] [Google Scholar]
  42. McFarland J., Anderson A.J., Slichter S.J. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates. Br J Haematol. 1989;73:380–386. doi: 10.1111/j.1365-2141.1989.tb07757.x. [DOI] [PubMed] [Google Scholar]
  43. Miller A.B., Hoogstraten B., Stachet M., et al. Reporting results of cancer treatment. Cancer. 1981;47:207–214. doi: 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  44. Mueller-Eckhardt C., Förster C., Kayser W., et al. Alloimmunthrombozytopenie der Neugeborenen durch thrombozytenspezifische Antikörper (Anti-PlA1) Dtsch Med Wochenschr. 1982;107:216–219. doi: 10.1055/s-2008-1069902. [DOI] [PubMed] [Google Scholar]
  45. Mueller-Eckhardt C., Kiefel V., Grubert A., Kroll H., Weisheit M., Schmidt S., Mueller-Eckhardt G., Santoso S. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet. 1989;1:363–366. doi: 10.1016/S0140-6736(89)91733-9. [DOI] [PubMed] [Google Scholar]
  46. Munksgaard L., Albjerg L., Lillevang S.T., Gahrn-Hansen B., Georgsen J. Detection of bacterial contamination of platelet components: six years’ experience with the BacT/Alert system. Transfusion. 2004;44:1166–1173. doi: 10.1111/j.1537-2995.2004.04019.x. [DOI] [PubMed] [Google Scholar]
  47. Murphy M.F., Waters A.H. Immunological aspects of platelet transfusions. Br J Haematol. 1985;60:409–414. doi: 10.1111/j.1365-2141.1985.tb07437.x. [DOI] [PubMed] [Google Scholar]
  48. Navarro J.T., Hernandez J.A., Ribera J.M., Sancho J.M., Oriol A., Pujol M., Milla F., Feliu E. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL. Haematologica. 1998;83:998–1000. [PubMed] [Google Scholar]
  49. O’Connell B.A., Lee E.J., Rothko K., Hussein M.A., Schiffer C.A. Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates. Blood. 1992;79:527–531. [PubMed] [Google Scholar]
  50. Petz L.D., Garratty G., Calhoun L., et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion. 2000;40:1446–1456. doi: 10.1046/j.1537-2995.2000.40121446.x. [DOI] [PubMed] [Google Scholar]
  51. Rebulla P., Finazzi G., Marangoni F., Avvisati G., Gugliotta L., Tognoni G., Barbui T., Mandelli F., Sirchia G. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. N Engl J Med. 1997;337:1870–5. doi: 10.1056/NEJM199712253372602. [DOI] [PubMed] [Google Scholar]
  52. Roth W.K., Seifried E. The German Experience with NAT. Transfusion Med. 2002;12:255–258. doi: 10.1046/j.1365-3148.2002.00383.x. [DOI] [PubMed] [Google Scholar]
  53. Sagmeister M., Oec L., Gmur J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood. 1999;93:3124–6. [PubMed] [Google Scholar]
  54. Samama C.M., Bastien O., Forestier F., et al. Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001 — summary statement. Can J Anesth. 2002;49:S26–35. [PubMed] [Google Scholar]
  55. Samama C.M., Djoudi R., Lecompte T., Nathan-Denizot N., Schved J.-F., the AFSSAPS Expert Group Perioperative platelet transfusion: recommendations of the agence française de sécurité sanitaire des produits de santé (AFSSaPS) 2003. Can J Anesth. 2005;52:30–37. doi: 10.1007/BF03018577. [DOI] [PubMed] [Google Scholar]
  56. Slichter S.J. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfusion Medicine Reviews. 2004;18:153–167. doi: 10.1016/j.tmrv.2004.03.003. [DOI] [PubMed] [Google Scholar]
  57. Schnaidt M, Northoff H, Wernet D (v) Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic disorders. Transfus Med 6: 111–114 [DOI] [PubMed]
  58. Stainsby D., MacLennan S., Hamilton P.J. Management of massive blood loss: a template guide. Br J Anaesth. 2000;85:487–491. doi: 10.1093/bja/85.3.487. [DOI] [PubMed] [Google Scholar]
  59. Stanworth SJ, Hyde C, Heddle N, Rebulla P, Brunskill S, Murphy MF (v) Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 4: CD004269 [review] [DOI] [PubMed]
  60. Stark K., Werner E., Seeger E., Offergeld R., Altmann D., Kramer M.H. Infections with HIV, HBV, and HCV among Blood Donors in Germany 1998 and 1999. Infus Ther Transfus Med. 2002;29:305–307. [Google Scholar]
  61. Strindberg J., Berlin G. Transfusion of platelet concentrates — clinical evaluation of two preparations. Eur J Haematol. 1996;57:307–311. doi: 10.1111/j.1600-0609.1996.tb01382.x. [DOI] [PubMed] [Google Scholar]
  62. Tinmouth A., Tannock I.F., Crump M., Tomlinson G., Brandwein J., Minden M., Sutton D. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion. 2004;44:1711–1719. doi: 10.1111/j.0041-1132.2004.04118.x. [DOI] [PubMed] [Google Scholar]
  63. Vandermeulen E.P., Van Aken H., Vermylen J. Anticoagulants and spinal-epidural anaesthesia. Anesth Analg. 1994;79:1165–1177. doi: 10.1213/00000539-199412000-00024. [DOI] [PubMed] [Google Scholar]
  64. Wandt H., Ehninger G., Gallmeier W.M. New strategies for prophylactic platelet transfusion in patients with hematologic diseases. Oncologist. 2001;6:446–450. doi: 10.1634/theoncologist.6-5-446. [DOI] [PubMed] [Google Scholar]
  65. Wandt H., Frank M., Ehninger G., Schneider C., et al. Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91:3601–3606. [PubMed] [Google Scholar]
  66. Weis S.M., Hert R.C., Gianola F.J., Clark J.G., Crawford S.W. Complications of fiberoptic bronchoscopy in thrombocytopenic patients. Chest. 1993;104:1025–1028. doi: 10.1378/chest.104.4.1025. [DOI] [PubMed] [Google Scholar]
  67. Williamson L.M., Hackett G., Rennie J. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood. 1998;92:2280–2287. [PubMed] [Google Scholar]
  68. Zalneraitis E.L., Young R.S.K., Krishnamoorthy K.S. Intracranial hemorrhage in utero as a complication of isoimmune thrombocytopenia. J Pediatr. 1979;95:611–614. doi: 10.1016/S0022-3476(79)80781-7. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Abkowitz J.L., Chen J. Studies of c-Mpl function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones. Blood. 2007;109:5186–5190. doi: 10.1182/blood-2006-08-044503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Avecilla S.T., Hattori K., Heissig B., et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2004;10:64–71. doi: 10.1038/nm973. [DOI] [PubMed] [Google Scholar]
  3. Basser R.L., O’Flaherty E., Green M., Edmonds M., Nichol J., Menchaca D.M., Cohen B., Begley C.G. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002;99:2599–2602. doi: 10.1182/blood.V99.7.2599. [DOI] [PubMed] [Google Scholar]
  4. Basser R.L., Underhill C., Davis I., et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol. 2000;18:2852–2861. doi: 10.1200/JCO.2000.18.15.2852. [DOI] [PubMed] [Google Scholar]
  5. Basser R.L., Rasko J.E., Clarke K., et al. Randomized, blinded, placebocontrolled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89:3118–3128. [PubMed] [Google Scholar]
  6. Basser R.L., Rasko J.E., Clarke K., et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet. 1996;348:1279–1281. doi: 10.1016/S0140-6736(96)04471-6. [DOI] [PubMed] [Google Scholar]
  7. Bolwell B., Vredenburgh J., Overmoyer B., Gilbert C., Chap L., Menchaca D.M., Cruickshank S., Glaspy J. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant. 2000;26:141–145. doi: 10.1038/sj.bmt.1702465. [DOI] [PubMed] [Google Scholar]
  8. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–47. doi: 10.1056/NEJMoa073275. [DOI] [PubMed] [Google Scholar]
  9. Bussel J.B., Cheng G., Saleh M., Kovaleva L., Stone N., Mayer B., Jenkins J., Provan A. Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor. ASH Annual Meeting Abstracts. 2006;108:475. [Google Scholar]
  10. Bussel J.B., Kuter D.J., George J.N., et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672–1681. doi: 10.1056/NEJMoa054626. [DOI] [PubMed] [Google Scholar]
  11. Cerneus D., Brown K., Harris R., et al. Stimulation of Platelet Production in Healthy Volunteers by a Novel Pegylated Peptide-Based Thrombopoietin (TPO) Receptor Agonist. ASH Annual Meeting Abstracts. 2005;106:1249. [Google Scholar]
  12. Cwirla S.E., Balasubramanian P., Duffin D.J., et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science. 1997;276:1696–1699. doi: 10.1126/science.276.5319.1696. [DOI] [PubMed] [Google Scholar]
  13. de Sauvage F.J., Hass P.E., Spencer S.D., et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533–538. doi: 10.1038/369533a0. [DOI] [PubMed] [Google Scholar]
  14. Desjardins R.E., Tempel D.L., Lucek R., Kuter D.J. Single and Multiple Oral Doses of AKR-501 (YM477) Increase the Platelet Count in Healthy Volunteers. ASH Annual Meeting Abstracts. 2006;108:477. [Google Scholar]
  15. Doshi P.D., Giri J.G., Abegg A.L., et al. Promegapoietin, a family of chimeric growth factors, supports megakaryocyte development through activation of IL-3 and c-Mpl ligand signaling pathways. Exp Hematol. 2001;29:1177–1184. doi: 10.1016/S0301-472X(01)00694-4. [DOI] [PubMed] [Google Scholar]
  16. Douglas V.K., Tallman M.S., Cripe L.D., Peterson L.C. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol. 2002;117:844–850. doi: 10.1309/09NP-3DFG-BLM9-E5LE. [DOI] [PubMed] [Google Scholar]
  17. Fibbe W.E., Heemskerk D.P., Laterveer L., Pruijt J.F., Foster D., Kaushansky K., Willemze R. Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Blood. 1995;86:3308–3313. [PubMed] [Google Scholar]
  18. Frederickson S., Renshaw M.W., Lin B., et al. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. Proc Natl Acad Sci USA. 2006;103:14307–14312. doi: 10.1073/pnas.0602658103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Jenkins J.M., Williams D., Deng Y., Uhl J., Kitchen V., Collins D., Erickson-Miller C.L. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109:4739–4741. doi: 10.1182/blood-2006-11-057968. [DOI] [PubMed] [Google Scholar]
  20. Kai M., Motoki K., Yoshida H., et al. Domain Subclass Conversion Improved Activity of Anti-Mpl Agonist Antibodies in the Form of Whole IgG. ASH Annual Meeting Abstracts. 2006;108:1134. [Google Scholar]
  21. Kelemen E., Cserhati I., Tanos B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol. 1958;20:350–355. doi: 10.1159/000205503. [DOI] [PubMed] [Google Scholar]
  22. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395–403. doi: 10.1016/S0140-6736(08)60203-2. [DOI] [PubMed] [Google Scholar]
  23. Kuter D.J. New thrombopoietic growth factors. Blood. 2007;109:4607–4616. doi: 10.1182/blood-2006-10-019315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kuter D.J., Goodnough L.T., Romo J., DiPersio J., Peterson R., Tomita D., Sheridan W., McCullough J. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood. 2001;98:1339–1345. doi: 10.1182/blood.V98.5.1339. [DOI] [PubMed] [Google Scholar]
  25. Li J., Yang C., Xia Y., Bertino A., Glaspy J., Roberts M., Kuter D.J. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241–3248. doi: 10.1182/blood.V98.12.3241. [DOI] [PubMed] [Google Scholar]
  26. McHutchison J.G., Dusheiko G., Shiffman M.L., et al. Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C. N Engl J Med. 2007;357:2237–47. doi: 10.1056/NEJMoa073255. [DOI] [PubMed] [Google Scholar]
  27. McHutchinson JG, Afdhal NH, Dusheiko G et al. (2006) Eltrombopag, an oral platelet growth factor, facilitates initiation of interferon therapy in subjects with HCV associated thrombocytopenia: results from a phase II placebo controlled, double-blind, dose-ranging study. Hepatology 44: Abstract 692A
  28. Nash R.A., Kurzrock R., DiPersio J., et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2000;6:25–34. doi: 10.1016/S1083-8791(00)70049-8. [DOI] [PubMed] [Google Scholar]
  29. Orita T., Tsunoda H., Yabuta N., et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood. 2005;105:562–566. doi: 10.1182/blood-2004-04-1482. [DOI] [PubMed] [Google Scholar]
  30. Scheding S., Bergmann M., Shimosaka A., Wolff P., Driessen C., Rathke G., Jaschonek K., Brugger W., Kanz L. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion. 2002;42:321–327. doi: 10.1046/j.1537-2995.2002.00047.x. [DOI] [PubMed] [Google Scholar]
  31. Schuster M.W., Beveridge R., Frei-Lahr D., et al. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol. 2002;30:1044–1050. doi: 10.1016/S0301-472X(02)00878-0. [DOI] [PubMed] [Google Scholar]
  32. Somlo G., Sniecinski I., ter Veer A., et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood. 1999;93:2798–2806. [PubMed] [Google Scholar]
  33. Vadhan-Raj S., Patel S., Bueso-Ramos C., et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol. 2003;21:3158–3167. doi: 10.1200/JCO.2003.08.003. [DOI] [PubMed] [Google Scholar]
  34. Vadhan-Raj S., Murray L.J., Bueso-Ramos C., et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med. 1997;126:673–681. doi: 10.7326/0003-4819-126-9-199705010-00001. [DOI] [PubMed] [Google Scholar]
  35. Vadhan-Raj S. Recombinant human thrombopoietin: clinical experience and in vivo biology. Semin Hematol. 1998;35:261–268. [PubMed] [Google Scholar]
  36. Wang B., Nichol J.L., Sullivan J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76:628–638. doi: 10.1016/j.clpt.2004.08.010. [DOI] [PubMed] [Google Scholar]

Articles from Hämostaseologie are provided here courtesy of Nature Publishing Group

RESOURCES